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Several  candidate  human  schistosomiasis  vaccines  are  in  different  stages  of  preclinical  and  clinical  devel-
opment.  The  major  targets  are  Schistosoma  haematobium  (urogenitial  schistosomiasis)  and Schistosoma
mansoni  (intestinal  schistosomiasis)  that  account  for 99%  of the  world’s  252 million  cases,  with  90%  of
these  cases  in  Africa.  Two  recombinant  S. mansoni  vaccines  – Sm-TSP-2  and  Sm-14  are  in  Phase  1  trials,
while  Smp80  (calpain)  is undergoing  testing  in  non-human  primates.  Sh28GST,  also  known  as  Bilhvax  is
in  advanced  clinical  development  for  S. haematobium  infection.  The  possibility  remains  that  some  of these
vaccines  may  cross-react  to  target  both  schistosome  species.  These  vaccines  were  selected  on the basis
of their  protective  immunity  in  preclinical  challenge  models,  through  human  immune-epidemiological
studies or both.  They  are  being  advanced  through  a  combination  of academic  research  institutions,  non-
proﬁt  vaccine  product  development  partnerships,  biotechnology  companies,  and  developing  country
vaccine  manufacturers.  In addition,  new  schistosome  candidate  vaccines  are  being  identiﬁed  through
bioinformatics,  OMICs  approaches,  and  moderate  throughput  screening,  although  the  full potential  of
reverse  vaccinology  for schistosomiasis  has  not  yet  been  realized.  The  target  product  proﬁles  of these
vaccines  vary  but many  focus  on  vaccinating  children,  in  some  cases  following  mass  treatment  with praz-
iquantel,  also  known  as vaccine-linked  chemotherapy.  Several  regulatory  pathways  have  been  proposed,
some  of  which  rely  on  World  Health  Organization  prequaliﬁcation.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CCSchistosomes are snail-transmitted, water-borne parasitic
latyhelminthes (order Trematoda) that are found in fresh water
odies in low- and middle-income countries. Current estimates
rom the Global Burden of Disease Study 2010 (GBD 2010) sug-
est that 252 million people are infected with schistosomes, 90%
f whom live in sub-Saharan Africa [1]. The World Health Orga-
ization (WHO) reports that in 2014 at least 258 million people
orldwide required frequent and regular preventive treatment for
chistosomiasis [2]. Recently though, the disease even emerged in
urope on the French island of Corsica [3]. Globally two-thirds of
he cases are infected with Schistosoma haematobium (the cause
f urogenital schistosomiasis), one-third with Schistosoma mansoni
the cause of intestinal schistosomiasis), and 1% with Schistosoma
∗ Corresponding author at: Sabin Vaccine Institute and Texas Children’s Hospital
enter for Vaccine Development, Houston, TX, USA.
E-mail addresses: hotez@bcm.edu, nwwolf@bcm.edu (P.J. Hotez).
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.079
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceBY  license  (http://creativecommons.org/licenses/by/3.0/).
japonicum or Schistosoma mekongi (the causes of intestinal schis-
tosomiasis in East Asia). Schistosomiasis, together with hookworm
and leishmaniasis, rank as those neglected tropical diseases with
the highest disease burden as deﬁned by disability-adjusted life
years (DALYs) [1]. While the GBD 2010 estimated that the world lost
3.3 million DALYs from schistosomiasis in 2010 [1], other estimates
suggest that DALYs lost may  even be an order of magnitude higher if
chronic morbidities such as malnutrition, inﬂammation, and pain
are also taken into consideration [4,5]. In addition, there is some
evidence that S. haematobium may  represent an important risk fac-
tor for HIV/AIDS acquisition because of the mucosal inﬂammation
and ulceration caused by genital schistosomiasis in tens of millions
of girls and women [6,7]. In addition to S. haematobium-HIV co-
infections, S. mansoni and malaria co-infections are also widespread
in Africa, and may  result in synergistic effects [8].
Schistosomes reproduce by asexual reproduction in fresh-
water snails and are released in large numbers as infective
larvae. In water, these cercariae penetrate the skin of a human
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ost, transforming into schistosomulae that migrate through the
loodstream and lungs to the liver where they become adult
ale-female schistosomes. In the host’s mesenteric or bladder
enules, the adult schistosomes release their eggs into the tissues
efore some make their way into the feces or urine. Upon contact
ith fresh water, the eggs hatch and give rise to miracidia that
nter the intermediate hosts, snails.
The pathogenesis of human schistosomiasis begins when eggs
estined for exit out of the body through feces or urine, instead
ecome embedded in the tissues of the human intestine or bladder.
hese trapped eggs subsequently induce inﬂammation, granulo-
as, and ﬁbrosis leading to a number of clinical sequelae including
epatic ﬁbrosis and hepatosplenomegaly, hematuria, bladder ﬁbro-
is and obstruction, hydronephrosis and chronic renal disease.
. haematobium ova can also elicit vaginal or cervical inﬂamma-
ion (so-called “sandy patches”) that increases the risk of HIV/AIDS
cquisition, such that schistosomiasis is considered an important
o-factor in Africa’s AIDS epidemic [6]. Moreover, infection with S.
aematobium is strongly associated with squamous cell carcinoma
f the bladder [9]. Chronic schistosomiasis, in addition, can lead to
any other sequelae as well, especially in children, including but
ot limited to anemia, chronic pain, undernutrition, growth failure
nd cognitive deﬁcits [4,5].
Strategies to control schistosomiasis center on Mass Drug
dministration (MDA) of an acylated quinoline-pyrazine known as
raziquantel (PZQ). While less than 20% of children who  need PZQ
DA  actually receive regular treatments, the fact that the preva-
ence of schistosomiasis may  have increased over the last two to
hree decades [10], suggests that MDA  with PZQ alone will not be
dequate for the global elimination of schistosomiasis. Indeed, a
urvey of almost 400 experts on neglected tropical diseases con-
luded that schistosomiasis may  not be eliminated through current
pproaches [11]. A major reason is that MDA  does not interrupt
ransmission and does not prevent schistosome reinfection. With
he added potential for the emergence of PZQ resistance [12,13],
here is thus an urgent need for vaccines as an alternative approach
o lower the disease burden, limit transmission and mitigate the
orbidity of schistosomiasis [14,15].
. Biological feasibility for vaccine development
Immunity as a result of natural exposure to a pathogen is often
aken as evidence of the biological feasibility for vaccine develop-
ent. In the case of human schistosomiasis, rates and intensity
f infection tend to diminish with age, especially after puberty.
owever, it is unclear if acquired immunity is solely responsi-
le for this observation. Furthermore, the likelihood that such
mmunity is partly due to an IgE-mediated mechanism compli-
ates strategies that try to mimic  natural immunity. The goal of
mmunization, therefore, may  not be sterilizing immunity but the
ong-term reduction of both ova burden in the host tissues and
xcretion from the host, leading to diminished pathogenicity and
educed transmission, respectively.
The feasibility of schistosomiasis vaccines has been demon-
trated in a series of proof-of-concept studies where mice and
on-human primates (NHPs) were immunized with radiation-
ttenuated cercariae, and were found to be protected (with
fﬁcacies of >80%) against percutaneous schistosomal challenge
16–18]. Vaccinated mice exhibited both cellular and humoral
mmune responses to lung-stage parasites [19], and under some
ircumstances, the co-administration of the cercarial vaccine with
nterleukin-12 adjuvant improved protective immunity [20,21].
lthough an attenuated cercarial vaccine may  not be a viable
pproach in humans due to a number of factors including feasibility
f production, quality control, and safety, it represents a model for34 (2016) 2988–2991 2989
identifying meaningful correlates of immunity, particularly for the
design of a recombinant immunogen.
2. General approaches to vaccine development for low- and
middle-income country markets
Schistosomes do not multiply in the human host, and most of
the pathology comes as a consequence of the deposition of schisto-
some eggs in the tissues that lead to end-organ damage associated
with ﬁbrosis, inﬂammation, and bleeding. Current vaccine develop-
ment strategies aim to prevent schistosome infection and/or reduce
ova burden through the interruption of parasite reproduction. Thus,
among the major vaccine targets are the migrating schistosomulum
stages as well as adult females.
In the 1990s, an independent, WHO/TDR-sponsored evaluation
of six S. mansoni vaccine candidates in preclinical development
found that none achieved better than 40% efﬁcacy in reducing worm
load.
Since then the maturing of several new technologies, including
OMICs (e.g., genomics, proteomics, transcriptomics), microarrays,
and immunomic proﬁling, have helped in the identiﬁcation of
promising new target schistosome antigens [22–24]. However,
both inadequate funding and infrastructure for vaccine devel-
opment have slowed the translation of these antigen discovery
technologies to the clinic. Indeed the overall pipeline of human
schistosomiasis vaccines currently in clinical trials is extremely
modest especially when considering the high disease burden
of schistosomiasis and its potential role in Africa’s AIDS epi-
demic.
For S. haematobium,  a single candidate molecule, Sh28GST (Bil-
hvax), a schistosome glutathione S-transferase common to the
schistosomula and adult stages, is believed to currently be under-
going testing. Early phases 1 and 2 clinical trials conducted in
Niger and Senegal have demonstrated an acceptable safety proﬁle
and induction of high IgG3 antibody titers that have neutralized
Sh28GST activity and reduced egg-production, an effect that could
lead to decrease urinary tract pathology and transmission [25,26].
A phase 3 trial to evaluate if the vaccine candidate and PZQ admin-
istration would delay pathologic relapses of the S. haematobium
infection in infected children was conducted from 2009 to 2012,
but no results have been reported yet [27].
There are two  vaccine candidates for intestinal schistosomiasis
caused by S. mansoni in early stage clinical testing. The ﬁrst com-
prises the extracellular domain of an integral membrane S. mansoni
surface protein, Sm-TSP-2, that is bound by IgG1 and IgG3 anti-
bodies from individuals that have cleared infection [28]. Preclinical
studies in mice have shown that immunization with this protein
subunit substantially reduces worm burden. This immunogen has
been successfully expressed in yeast (Pichia pastoris) for scale-up
cGMP production [29,30], and is currently in phase 1 trials in Hous-
ton, Texas, USA. A second vaccine candidate in clinical testing is
based on Sm-14, a fatty acid binding protein from S. mansoni, and
it was  announced that this vaccine will undergo phase 1 trials in
Brazil [31]. While not yet in clinical development, Smp80 (calpain)
has demonstrated efﬁcacy in NHP challenge studies, and will also
likely advance to the clinic [32]. As Asian schistosomiasis caused
by S. japonicum is an important zoonosis, there is increased inter-
est here in developing a veterinary vaccine for water buffalo, cattle,
and pigs as a potential means toward blocking a transmission to
humans [33].
Because several of the antigens under investigation are highly
conserved among different species, there is some optimism for
advancing a pan-schistosome vaccine, especially for S. mansoni
and S. haematobium co-infection, prevalent in sub-Saharan Africa.
In addition, because of the geographic overlap between schis-
tosomiasis and hookworm disease, there have also been early
2990 M. Merriﬁeld et al. / Vaccine 34 (2016) 2988–2991
Table  1
Current vaccines in clinical trials (POC = proof of concept trial).
Parasite species targeted Vaccine Major antigens/adjuvants Sponsor Status
Schistosoma haematobium Bilhvax Sh28GST (28-kDa recombinant
glutathione-S-transferase)
Alum formulation
Institut Pasteur and INSERM Completed Phase 2 and 3 trials
in West Africa (results
pending) [15,27].
Schistosoma mansoni Sm-TSP-2 Sm-TSP-2 (9-kDa recombinant
tetraspanin)
Alhydrogel® ± GLA
Sabin Vaccine Institute Product
Development Partnership/NIAID,
NIH/Baylor College of Medicine
Vaccine and Treatment Evaluation
Unit
Initiated Phase 1 trial in 2014
at Baylor College of Medicine
[39].
ith
Oswaldo Cruz Foundation (Fiocruz)
Oroﬁno
Ongoing phase 1 trial [40].
Phase 2 trials are planned for
2015 in Brazil and Africa.
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Table 2
Development status of schistosomiasis vaccine candidates (POC = proof of concept
trial) [12,15].
Candidate name/identiﬁer Preclinical Phase I Phase II Phase III
Sm-TSP-2 X
Sm-TSP-1 X
Sm29 X
Sm23 X
Smp80 X
Sh28GST X
Sm-14 XS.  mansoni Sm-14 Sm-14 (14-kDa recombinant
fatty acid binding protein) w
the adjuvant GLA
onsiderations to develop a multivalent vaccine that targets both
elminths [34]. The general approach would then be to tar-
et school-aged children in hyperendemic areas with broadly
mmunogenic and durable vaccines of relatively low cost and
xtended shelf-life. An additional potential beneﬁt would be the
eduction of HIV/AIDS transmission through the prevention of uro-
enital schistosomiasis [7].
A schistosomiasis vaccine could be developed either as a stand-
lone technology or used as a companion technology alongside
DA. Towards this goal Bergquist and colleagues have made cogent
rguments for shaping a “vaccine-linked chemotherapy” strategy
hat would initially implement MDA  with PZQ followed by immu-
ization to prevent reinfection [35].
. Technical and regulatory assessment
The pathway toward regulatory approval of these vaccine can-
idates will likely require at least a 40% reduction of worm burden.
he schistosome antigens and prototype vaccine formulations cur-
ently in early clinical testing induce 30–70% reductions in worm
urden or egg production and have succeeded to increase viabil-
ty in laboratory animals. The challenge though remains in the
ranslation of these antigens into humans and maintain a similar
r superior protection through formulation with novel adjuvants,
ncluding the use of Toll-like receptor agonists such as synthetic
ipid A molecules. The immune correlates of protection for a schis-
osomiasis vaccine are thought to be observable in IgG1 and IgG3
ntibody recognition of the antigens. The standard animal model
or screening potential antigens has been the mouse model used to
est the efﬁcacy of schistosomiasis vaccines, but SmP80 is now also
ndergoing extensive testing in NHPs [36].
Several additional factors must be taken into consideration
or a successful vaccine development in low- and middle-income
ountries including the choice of antigen and target species (e.g.,
. haematobium, S. mansoni or both), production feasibility and
ost per dose. Careful antigen and adjuvant selection, cutting edge
mmunogen design based on potential immune correlates, and
obust efﬁcacy in laboratory animal models will not be sufﬁcient
or a successful vaccine if cGMP manufacturing of the vaccine prod-
ct is not feasible [12]. Currently, recombinant vaccines for NTDs
re thus mostly produced in low-cost bacteria or yeast expression
ystems. It will also be important to select the appropriate adjuvant
nd delivery platform to stimulate the correct immune response.
n additional challenge here has been the limited availability of
djuvants with regulatory approval for use in humans.
. Status of vaccine R&D activitiesThe vaccine candidates currently in clinical trials are listed in
ables 1 and 2. Some of the progress in developing these promis-
ng vaccine candidates has come from screening schistosomeSj97 paramyosin X
CT-SOD X
OMICs databases through DNA microarray proﬁling, proteomics,
glycomics, and immunomics have helped identify promising
immunogens [22–24,37]. Further signiﬁcant advancement has
been achieved through the successful application of RNA interfer-
ence (RNAi) technology, which in the case of Sm-TSP-2 allowed
investigators to ascribe speciﬁc functions to the molecule and
its role in parasite survival [38]. Complexities of advancing true
reverse vaccinology approaches (as was successfully done for
meningococcus) include large genome sizes, and the requirement
for eukaryotic expression systems, as well as cumbersome labora-
tory animal model systems.
5. Likelihood for ﬁnancing
According to the public search tool, G-Finder, between 2007
and 2013, approximately $27 million in funding was awarded
for schistosomiasis vaccine research and development (R&D), pri-
marily from major public sector funding agencies such as the
Australian National Health and Medical Research Council (NHMRC),
France’s Institut national de la santé et de la recherche médicale
(INSERM), the Brazilian Ministry of Health’s Department of Sci-
ence and Technology (DECIT), the European Commission, and the
US National Institutes of Health (NIH) [41]. Through a group of
philanthropic donors, including the Michelson Medical Research
Foundation and the Blavatnik Family Foundation the Sabin Vaccine
Institute Product Development Partnership (Sabin PDP) has also
funded schistosomiasis vaccine R&D efforts to a total of approxi-
mately US$1.25 million, with additional NIH support for toxicology
testing and for the phase 1 trial. New and increased ﬁnancing from
major funders will be critical to advance these candidate vaccines.
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